IS7097A - Medicinal product for the administration of intramuscular filvestrant - Google Patents

Medicinal product for the administration of intramuscular filvestrant

Info

Publication number
IS7097A
IS7097A IS7097A IS7097A IS7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A IS 7097 A IS7097 A IS 7097A
Authority
IS
Iceland
Prior art keywords
filvestrant
intramuscular
administration
medicinal product
medicinal
Prior art date
Application number
IS7097A
Other languages
Icelandic (is)
Inventor
Kay Cahill Julie
Richard Gellert Paul
Marshall Irving Alan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0116619.8A external-priority patent/GB0116619D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of IS7097A publication Critical patent/IS7097A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IS7097A 2001-07-07 2004-01-05 Medicinal product for the administration of intramuscular filvestrant IS7097A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0116619.8A GB0116619D0 (en) 2001-07-07 2001-07-07 Formulation
US31571101P 2001-08-30 2001-08-30
PCT/GB2002/003092 WO2003006064A1 (en) 2001-07-07 2002-07-03 Pharmaceutical formulation for the intramuscular administration of fulvestrant

Publications (1)

Publication Number Publication Date
IS7097A true IS7097A (en) 2004-01-05

Family

ID=26246290

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7097A IS7097A (en) 2001-07-07 2004-01-05 Medicinal product for the administration of intramuscular filvestrant

Country Status (15)

Country Link
EP (1) EP1406662A1 (en)
JP (1) JP2004534093A (en)
CN (1) CN1553815A (en)
AR (1) AR037138A1 (en)
BR (1) BR0210898A (en)
CA (1) CA2453111A1 (en)
CO (1) CO5560585A2 (en)
HU (1) HUP0400115A3 (en)
IL (1) IL159576A0 (en)
IS (1) IS7097A (en)
MX (1) MXPA04000028A (en)
NO (1) NO20040047L (en)
PL (1) PL367624A1 (en)
RU (1) RU2004102393A (en)
WO (1) WO2003006064A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
EP2417975A4 (en) 2009-08-31 2012-11-14 Xi An Libang Medical Technology Co Ltd Fulvestrant nanosphere/microsphere and preparative method and use thereof
CN102600064A (en) * 2012-03-31 2012-07-25 西安力邦制药有限公司 Fulvestrant or fulvestrant derivative sustained release preparation and preparation method thereof
CN102600065B (en) * 2012-03-31 2014-08-13 莱普德制药有限公司 Fulvestrant or fulvestrant derivative oily preparation and preparation method thereof
CN102600073B (en) * 2012-03-31 2014-01-01 莱普德制药有限公司 Lactate-based fulvestrant or fulvestrant derivative oily preparation and preparation method of oily preparation
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
EP3441073B1 (en) * 2016-04-06 2022-02-23 FUJIFILM Corporation Medicinal composition comprising fulvestrant
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of using them
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
EP3466430B1 (en) 2016-05-31 2020-04-29 FUJIFILM Corporation Pharmaceutical composition
JP7220712B2 (en) 2017-11-08 2023-02-10 イーグル ファーマスーティカルズ、インク. Fulvestrant Formulations and How to Use Them
US20210169897A1 (en) * 2017-12-07 2021-06-10 Nevakar Inc. Concentrated Fulvestrant Compositions
WO2019151353A1 (en) * 2018-01-31 2019-08-08 富士フイルム株式会社 Method for producing preparation for injection
CN111481559B (en) * 2019-01-25 2021-10-08 江苏恒瑞医药股份有限公司 High-concentration fulvestrant composition and preparation method thereof
US12377049B2 (en) 2019-12-11 2025-08-05 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
WO2023121232A1 (en) * 2021-12-20 2023-06-29 주식회사 삼양홀딩스 Pharmaceutical composition of fulvestrant having improved solubility, and method for preparing same
CN118717660B (en) * 2024-06-12 2025-02-28 湖州亚瑟制药有限公司 Fulvestrant pharmaceutical composition for injection and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
GB0008172D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Therapy

Also Published As

Publication number Publication date
JP2004534093A (en) 2004-11-11
HUP0400115A2 (en) 2004-06-28
EP1406662A1 (en) 2004-04-14
PL367624A1 (en) 2005-03-07
RU2004102393A (en) 2005-03-27
NO20040047L (en) 2004-02-23
BR0210898A (en) 2004-06-22
WO2003006064A1 (en) 2003-01-23
CO5560585A2 (en) 2005-09-30
AR037138A1 (en) 2004-10-27
IL159576A0 (en) 2004-06-01
CA2453111A1 (en) 2003-01-23
CN1553815A (en) 2004-12-08
MXPA04000028A (en) 2004-05-21
HUP0400115A3 (en) 2005-11-28

Similar Documents

Publication Publication Date Title
NO20033384L (en) Pharmaceutical Formulation
IS6994A (en) Aripiprazole solution for oral administration
NO20033785D0 (en) Pharmaceutical formulation
IS6986A (en) Liquid pharmaceutical composition
DE60220661D1 (en) TRANSDERMALES PLASTER FOR THE ADMINISTRATION OF FENTANYL
NO20033556L (en) Pharmaceutical Formulations
FI20011478A0 (en) Pharmaceutical composition
ITTO20010008A0 (en) PHARMACEUTICAL FORMULATION
EE05020B1 (en) The pharmaceutical composition of G1buride
NO20035627D0 (en) Pharmaceutical formulation
HUP0400200A3 (en) Pharmaceutical formulation for the efficient administration of apomorphine, 6ar-(-)-n-propyl-norapomorphine and their derivatives and pro-drugs thereof
NO20041315L (en) Drug Delivery System
EE200300589A (en) Pharmaceutical compositions
NO20040047L (en) Pharmaceutical formulation for intramuscular administration of fulvestrant
DE60203537D1 (en) 5HT1-RECEPTORAGONIST-CONTAINING MEDICAMENT
NO20040860L (en) Pharmaceutical composition including lumiracoxib
NO20034556D0 (en) Imidazotriazinone-containing compositions for nasal administration
NO20041485L (en) Pharmaceutical formulation comprising (R) -bicalutamide
DK1475379T3 (en) Use of scopin ester derivatives for the manufacture of drugs
NO20042640L (en) Process for the preparation of echinocandin derivatives
DK1385512T3 (en) Use of pyridoindolone derivatives for the preparation of anticancer drugs
FI20010892A0 (en) Process for the preparation of xylitol
FI20012242A0 (en) New pharmaceutical compounds
NO20041236L (en) Pharmaceutical Formulation
NO20040312L (en) Process for the preparation of pharmaceutical preparations